- First Online:
- 159 Downloads
▲ Pregabalin is the pharmacologically active S-enantiomer of 3-aminomethyl-5-methyl-hexanoic acid. It has a similar pharmacological profile to that of its developmental predecessor gabapentin, but had greater analgesic activity in rodent models of neuropathic pain.
▲ Pregabalin is thought to act by reducing the excessive release of several excitatory neurotransmitters by binding to the α2-δ protein subunit of voltage-gated calcium channels.
▲ Oral pregabalin 150–600 mg/day, administered in two or three divided doses, was significantly more effective than placebo in relieving pain and improving pain-related sleep interference in four randomized, double-blind, multicentre studies of 4–13 weeks’ duration in patients with postherpetic neuralgia (PHN).
▲ Pregabalin achieved a faster onset of pain relief than placebo. The median times to the onset of pain relief with fixed and flexible doses of pregabalin were 1.5 and 3.5 days compared with <4 weeks with placebo.
▲ Pregabalin was generally well tolerated when titrated over 1 week to fixed dosages (maximum 600 mg/day) in clinical trials in mostly elderly PHN patients. Adverse events were usually mild to moderate in severity.
- 3.van Wijck AJM, Opstelten W, van Essen GA, et al. Long term follow-up of herpes zoster patients: a prospective cohort. In: van Wijck AJM. Postherpetic neuralgia [thesis]. Utrecht: Utrecht University, 2006: 60–70Google Scholar
- 6.Huckle R. Pregabalin Pfizer. Curr Opin Investig Drugs 2004; 5(1): 82–9Google Scholar
- 16.Pfizer. Lyrica® (pregabalin): full prescribing information [online]. Available from URL: http://www.pfizer.com/files/products/uspi_lyrica.pdf [Accessed 2009 May 19]
- 30.Bockbrader HN, Hunt T, Strand J, et al. Pregabalin pharmacokinetics and safety in healthy volunteers: results from two phase 1 studies. [abstract no. P06.051]. Neurology 2000 Apr; 54Suppl. 3: 421Google Scholar
- 33.Busch JA, Strand JC, Posvar EL, et al. Pregabalin (CL-1008) single-dose pharmacokinetics and safety/tolerance in healthy subjects after oral administration of pregabalin solution or capsule doses [abstract no. 2.108]. Epilepsia 1998; 39Suppl. 6: 58Google Scholar
- 44.European Medicines Agency. Lyrica® (pregabalin): summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/lyrica [Accessed 2009 May 19]